ArticleBritish journal of haematology2024

Therapeutic potential of the latest oxygen affinity-modifying agent, GBT021601, for treating sickle cell disease is questionable.

Braydon Alaimo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.